EA8185

ECOG-ACRIN/NRG Joint Study:A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study

Principal Investigator

Abhishek Solanki

Status

Disease Site

Genitourinary [GU] Bladder

Phase

II

Developmental Therapeutics

Yes

Primary Objective

To compare the clinical complete response rate [cCR] after chemoRT with or without MEDI4736 (durvalumab) in node-positive bladder cancer patients.

NOTE:

This is a Joint ECOG/ACRIN & NRG Oncology trial, with ECOG-ACRIN as the lead group for trial conduct. NRG Oncology institutions can credit NRG for their case accrual. 

ECOG-ACRIN Study Chair: Monika Joshi, MD, MRCP 

Patient Population

Patient with histologically proven pure or mixed urothelial cancer of the bladder (any T, N1-2 M0).

Target Accrual

114